MRNA vs PFE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PFE Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pfizer Inc. (PFE) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus PFE at 9.3x Forward P/E and 29.1% operating margin (-0.4% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against PFE sits in CONSOLIDATION (58th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | PFE Revenue | MRNA Op. Margin | PFE Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $40.8B | -306.0% | 27.3% | PFE |
| FY2019 | $60M | $40.9B | -906.8% | 39.2% | PFE |
| FY2020 | $800M | $41.6B | -95.0% | 22.0% | PFE |
| FY2021 | $18.5B | $73.6B | 72.0% | 29.8% | MRNA |
| FY2022 | $19.3B | $91.8B | 48.9% | 34.2% | MRNA |
| FY2023 | $6.85B | $50.9B | -61.9% | 4.2% | PFE |
| FY2024 | $3.24B | $63.6B | -121.9% | 12.6% | PFE |
| FY2025 | $1.94B | $62.6B | -158.1% | 12.4% | PFE |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | PFE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $157.0B | Larger Scale | PFE |
| Trailing P/E Ratio Valuation | 23.0x | 39.3x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 9.3x | Lower Multiple | PFE |
| Revenue Growth (YoY) Growth | +29.2% | -0.4% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 29.1% | Higher Margin | PFE |
| Net Profit Margin Profitability | -110.5% | 6.3% | Higher Margin | PFE |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 4.5% | Higher ROE | PFE |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 48% ($24โ$31) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.18ฮฒ ยท 22% Vol | Lower Realized Risk | PFE |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 49.4 / 100 (HOLD) | Higher Composite | PFE |